Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Cannabis Science In Final Negotiations To Purchase 50% Of Cancer Center

4/18/2012 2:29 PM ET

Biotech company Cannabis Science Inc. (CBIS.OB) Wednesday said it is in final negotiations to purchase 50 percent of a 10,000 square foot Cancer Center in Arizona.

Cannabis Science expects to sign the deal for the Cancer Centre within the next few days. Th company claims the acquisition to expand its patient support.

Click here to receive FREE breaking news email alerts for Cannabis Science, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. said Wednesday after the markets closed that its second quarter profit rose 7% from last year, as sales surged and margins improved amid strong sales of its iPhones. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave a slightly downbeat revenue forecast for the current quarter. Stocks moved mostly lower during trading on Wednesday, giving back some ground after trending higher over the past several sessions. Selling pressure was relatively subdued, however, limiting the downside for the markets. The major averages all closed in the red, although the tech-heavy Nasdaq underperformed its counterparts by a wide margin. Russian Foreign Minister Sergei Lavrov warned Wednesday that Moscow would retaliate strongly if its "interests" in Ukraine are attacked. He also criticized the Ukrainian administration for relaunching its so-called anti-terrorist operation in the east of the country a day earlier. Lavrov's remarks came in an interview with Russia Today, which published excerpts of the English-language interview to
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.